Q-omics provides the consensus-scored RPL14 profile across patient tissues and cancer cell-line models. RPL14 expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in BRCA. Among the 18 cancer types available for tumor–normal comparison, RPL14 is differentially expressed in 12, with the highest sampling consensus in KIRP. Additionally, RPL14 protein abundance shows 18,993 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight BRCA, KIRP, and GBM as cancer lineages where RPL14 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RPL14 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RPL14 survival associations across molecular data types. RPL14 RNA expression shows survival associations in the most cancer types (21), followed by mutation status (1) and mass-spec protein abundance (7). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RPL14 RNA expression–survival associations across cancer types. High RPL14 expression shows unfavorable associations in ACC, KICH and LIHC, but favorable associations in BRCA, UVM and LGG. The BRCA Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify BRCA as the clearest survival context for RPL14 RNA expression.
This table summarizes RPL14 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 7. The strongest signals are observed in HNSC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for RPL14. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RPL14 shows lower tumor expression in HNSC and BRCA and higher tumor expression in KIRP, KIRC, LIHC and COAD. The KIRP box plot shows higher RPL14 RNA expression in tumor versus normal tissue (log2 FC = +0.774, t-test p < 0.001).
This table shows molecular features associated with RPL14 in patient tissues and cancer cell lines. In patient samples, RPL14 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, RPL14 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_SCLC, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia and UPPER_AERODIGESTIVE_TRACT.
